Chaoling Wan

National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University

Affiliated withThe First Affiliated Hospital of Soochow University

Research Area

Biography

Chaoling Wan has not added Biography.
If you are Chaoling Wan and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 1	Year
Publication title	2025

Other Publications

Article	Year
Venetoclax combined with azacitidine as an effective and safe salvage regimen for relapsed or refractory T-cell acute lymphoblastic leukemia: a case series. Leukemia & lymphoma\| PubMed ID: 34323656	2021
A Phase II Trial of the Double Epigenetic Priming Regimen Including Chidamide and Decitabine for Relapsed/Refractory Acute Myeloid Leukemia. Frontiers in oncology\| PubMed ID: 34540696	2021
A Combined Histone Deacetylases Targeting Strategy to Overcome Venetoclax Plus Azacitidine Regimen Resistance in Acute Myeloid Leukaemia: Three Case Reports. Frontiers in oncology\| PubMed ID: 34956909	2021
Efficiency of anti-VEGF therapy in central nervous system AML relapse: A case report and literature review. Clinical case reports\| PubMed ID: 35140963	2022
Combination of Venetoclax and Midostaurin Efficiently Suppressed Relapsed t(8;21)Acute Myeloid Leukemia With Mutant KIT After Failure of Venetoclax Plus Azacitidine Treatment. Frontiers in oncology\| PubMed ID: 35211416	2022
Comparing the efficacy of salvage regimens for relapsed/refractory B-cell acute lymphoblastic leukaemia: a systematic review and network meta-analysis. Annals of hematology\| PubMed ID: 36394582	2023
Flumatinib plus venetoclax as an effective therapy for Philadelphia chromosome-positive acute myeloid leukemia: A case report. Clinical case reports\| PubMed ID: 36619491	2023
Metagenomic next-generation sequencing performed on blood samples for the early recognition of severe Pneumocystis pneumonia in critical hematological patients. Medicine\| PubMed ID: 37026960	2023
Rapid molecular response to dasatinib in Ph-like acute lymphoblastic leukemia patients with ABL1 rearrangements: case series and literature review. Annals of hematology\| PubMed ID: 37103615	2023
Safety and efficacy of CD22 and CD19 CAR-T bridging auto-HSCT as consolidation therapy for AYA and adult B-ALL. Blood cancer journal\| PubMed ID: 37137904	2023
Case Report: Blinatumomab therapy for the treatment of B-cell acute lymphoblastic leukemia patients with central nervous system infiltration. Frontiers in immunology\| PubMed ID: 37143650	2023
Targeted therapy and immunotherapy for T cell acute lymphoblastic leukemia/lymphoma. Annals of hematology\| PubMed ID: 37227492	2023
Mutation spectrum of FLT3 and significance of non-canonical FLT3 mutations in haematological malignancy. British journal of haematology\| PubMed ID: 37246158	2023
Preemptive inotuzumab ozogamicin eradicated measurable residual disease in Ph-negative acute lymphoblastic leukemia relapsed post CD19 CART therapy. Clinical case reports\| PubMed ID: 38084356	2023
Efficacy and safety of cladribine, low-dose cytarabine and venetoclax in relapsed/refractory acute myeloid leukemia: results of a pilot study. Blood cancer journal\| PubMed ID: 38238305	2024
Investigations of the prognostic value of RUNX1 mutation in acute myeloid leukemia patients: Data from a real-world study. Leukemia research\| PubMed ID: 38493755	2024
Clonal evolution from B-cell acute lymphoblastic leukemia with <I>BCR::ABL1</I> multilineage involvement to acute myeloid leukemia after multiple anti-CD19 chimeric antigen receptor T-cell t... Haematologica\| PubMed ID: 38961741	2024
Venetoclax with hypomethylating agents versus intensive chemotherapy in newly diagnosed acute myeloid leukemia with myelodysplasia related changes: A propensity score-matched analysis based ... Blood cancer journal\| PubMed ID: 39179571	2024
Quantification of the FLT3 internal tandem duplication is a reliable marker for monitoring measurable residual disease in acute myeloid leukemia with FLT3-ITD mutations. Bone marrow transplantation\| PubMed ID: 39658655	2025
Chidamide combined with azacitidine as a novel double epigenetic preemptive treatment for a myelodysplastic syndrome patient showing molecular relapse after allogeneic hematopoietic stem cel... Annals of hematology\| PubMed ID: 39668198	2024
Venetoclax plus hypomethylating agents versus priming regimen as the first-line therapy for newly diagnosed acute myeloid leukemia with myelodysplasia-related changes: a propensity score-mat... Leukemia & lymphoma\| PubMed ID: 41048093	2025
Phase II study of dual epigenetic targeting with chidamide and azacitidine in patients with high-risk acute myeloid leukemia after allo-HSCT. Clinical epigenetics\| PubMed ID: 41084078	2025
[A Study of Flow Sorting Lymphocyte Subsets to Detect Epstein-Barr Virus Reactivation in Patients with Hematological Malignancies]. Zhongguo shi yan xue ye xue za zhi\| PubMed ID: 41234101	2025
Venetoclax plus azacitidine in relapsed or refractory T-cell acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 trial. The Lancet. Haematology\| PubMed ID: 41338863	2025